Momentum, Growth & Innovation: Updated Watchlist www.tradingview.com My updated trading watchlist includes a diverse range of companies across various sectors, prominently featuring technology, healthcare, and finance, among others. These companies, currently part of ARK Invest's holdings, are identified as being in a confirmed Stage 2 uptrend, indicating strong...
Analyzing the options chain and the chart patterns of UPS United Parcel Service prior to the earnings report this week, I would consider purchasing the $42.50 strike price Calls with an expiration date of 2023-8-18, for a premium of approximately $0.37. If these options prove to be profitable prior to the earnings release, I would sell at least half of...
“A new clean energy economy is emerging, and it is emerging much faster than many stakeholders, policymakers, industry players, and investors think today” – Fatih Birol, Executive Director, IEA during the Global EV Outlook 2023 press event on 26 April 2023. The International Energy Agency (IEA) published its Global Electric Vehicle Outlook for 2023 on 26 April....
Ionis Pharmaceuticals, Inc. ( NASDAQ:IONS ) Sector: Health Technology (Pharmaceuticals: Major) Current Price: $46.36 Breakout price trigger: $47.85 Buy Zone (Top/Bottom Range): $44.65-$39.75 Price Target: $55.50-$56.30 Estimated Duration to Target: 131-139d Contract of Interest: $IONS 1/20/23 50c Trade price as of publish date: $3.20/cnt
Down trend since January highs after 1st qtr company report. Overall price has dropped over 45%. Potential consolidation with trend reversal. This stock has been on my radar the last 2-3 weeks as I have been evaluating and looking for signs of a reversal before going long. Ratings/analysis are mixed for this stock. I believe there is substantial uncertainty...
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare...
Hi Followers, Welcome to my page, I will be posting 10 charts on USA #STOCK #MARKET this month. #STOCKMARKET Using a Unique Technical Analysis invented by me. Later, if the charts work out, I will talk more about it. As far as our technical Analysis is identifying, there is a big possibility that this company is OVERBOUGHT, which opens a trade...
Spinning top candle RSI over bought Same run up after good earnings beat last quarter with the same result as this quarter Need one more correction before we can break above
IONS price going up with weekly trend line. possibly buy. wait for retracement. I also watching this one .
Fundamental score of 30 I just love that formation and CLEAR PRECISE trendline. It will get broken soon and fall alot. GL